New hope for teens with chronic Graft-Versus-Host disease: belumosudil under study

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant must be 12 to less than 18 years of age at the time of signing the informed consent. * Participant has undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT). * Has active moderate to severe cGVHD. * Has received at least one line of prior systemic therapy for cGVHD. * Participant must receive a corticosteroid therapy for cGVHD with a stable dose for at least 2 weeks prior to the first dose of the IMP. * Has a Lansky-Play performance score of ≥60. * Participants should have an expected survival of longer than 6 months. * Body weight of 30 kg and above. * Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * The participant or their legally authorized representative (LAR) must be capable of giving signed informed consent. Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: * Recurrence of hematologic neoplasms (according to the corresponding criteria for recurrence of primary hematologic neoplasms) or post-transplant lymphoproliferative disease at screening. * Received investigational systemic therapy for cGVHD within 28 days prior to enrollment, unless the prior treatment had been washed out for at least 28 days or 5 half-lives prior to enrollment, whichever is shorter. * Absolute neutrophil count (ANC) \<1.0 × 10\^9/L. * Platelet count \<50 × 10\^9/L. * Alanine aminotransferase (ALT) \>3× the upper limit of normal (ULN), aspartate aminotransferase (AST) \>3 × ULN. * Total bilirubin (TBIL) \>1.5 × ULN (\>3 ULN if Gilbert's syndrome). * Estimated Glomerular Filtration Rate (eGFR) \<30 mL/min/1.73 m\^2 using the revised Bedside Schwartz formula . Revised Schwartz equation: CrCl (mL/min/1.73 m\^2) = 0.413 × (height \[in cm\])/Creatinine (in mg/dL) at screening visit. * Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.